Cilostazol

CAT: 0804-HY-17464-01Size: 50 mgDry Ice: NoHazardous: No
CAT#:0804-HY-17464-01Size:50 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].
CAS Number
[73963-72-1]
Product Name Alternative
OPC 13013
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cardiovascular Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/Cilostazol.html
Purity
99.83
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1NC2=C(C=C(OCCCCC3=NN=NN3C4CCCCC4)C=C2)CC1
Molecular Formula
C20H27N5O2
Molecular Weight
369.46
Precautions
H302, H315, H319, H335
References & Citations
[1]Schr?r K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9.|[2]Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61 (25) :PL 383-9.|[3]Saito S, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res. 2013 Apr 19.|[4]Ye YL, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.Eur J Pharmacol. 2007 Feb 14;557 (1) :23-31. Epub 2006 Nov 10.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Alternative Products

CatalogName
BML-PD127-0050Cilostazol

Popular Products